272 related articles for article (PubMed ID: 11893233)
1. Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia.
McKeage K; Plosker GL
Drugs; 2002; 62(4):633-53. PubMed ID: 11893233
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group.
van Kerrebroeck P; Jardin A; Laval KU; van Cangh P
Eur Urol; 2000 Mar; 37(3):306-13. PubMed ID: 10720857
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study.
van Kerrebroec P; Jardin A; van Cangh P; Laval KU;
Eur Urol; 2002 Jan; 41(1):54-60; discussion 60-1. PubMed ID: 11999466
[TBL] [Abstract][Full Text] [Related]
4. Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia.
Guay DR
Am J Geriatr Pharmacother; 2004 Mar; 2(1):14-23. PubMed ID: 15555475
[TBL] [Abstract][Full Text] [Related]
5. Alfuzosin hydrochloride for the treatment of benign prostatic hyperplasia.
Lee M
Am J Health Syst Pharm; 2003 Jul; 60(14):1426-39. PubMed ID: 12892027
[TBL] [Abstract][Full Text] [Related]
6. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia.
Wilde MI; Fitton A; McTavish D
Drugs; 1993 Mar; 45(3):410-29. PubMed ID: 7682910
[TBL] [Abstract][Full Text] [Related]
7. Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects.
Ahtoy P; Chrétien P; Dupain T; Rauch C; Rouchouse A; Delfolie A
Int J Clin Pharmacol Ther; 2002 Jul; 40(7):289-94. PubMed ID: 12139205
[TBL] [Abstract][Full Text] [Related]
8. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
[TBL] [Abstract][Full Text] [Related]
9. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects.
MacDonald R; Wilt TJ
Urology; 2005 Oct; 66(4):780-8. PubMed ID: 16230138
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial.
Roehrborn CG
Urology; 2001 Dec; 58(6):953-9. PubMed ID: 11744466
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of a new once-a-day formulation of an alpha-blocker.
Van Kerrebroeck PE
Eur Urol; 2001 Mar; 39 Suppl 6():19-26. PubMed ID: 11306897
[TBL] [Abstract][Full Text] [Related]
13. Alfuzosin: overview of pharmacokinetics, safety, and efficacy of a clinically uroselective alpha-blocker.
Roehrborn CG
Urology; 2001 Dec; 58(6 Suppl 1):55-63; discussion 63-4. PubMed ID: 11750253
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies.
Roehrborn CG; Van Kerrebroeck P; Nordling J
BJU Int; 2003 Aug; 92(3):257-61. PubMed ID: 12887479
[TBL] [Abstract][Full Text] [Related]
15. Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study.
Roehrborn CG
BJU Int; 2006 Apr; 97(4):734-41. PubMed ID: 16536764
[TBL] [Abstract][Full Text] [Related]
16. Alfuzosin for symptomatic benign prostatic hyperplasia: long-term experience.
McVary KT
J Urol; 2006 Jan; 175(1):35-42. PubMed ID: 16406865
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group.
Buzelin JM; Roth S; Geffriaud-Ricouard C; Delauche-Cavallier MC
Eur Urol; 1997; 31(2):190-8. PubMed ID: 9076465
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia.
Kongkanand A; Chodchoy V; Lojanapiwat B; Pumpaisanchai S; Ratana-Olarn K; Sae-Tang P; Taweemonkongsap T
J Med Assoc Thai; 2009 Jul; 92(7):969-78. PubMed ID: 19626818
[TBL] [Abstract][Full Text] [Related]
19. Impact of alfuzosin on sexual function in Taiwanese men with benign prostatic hyperplasia.
Hwang TI; Chu SH; Lin MS; Chen CS; Lee LM; Chang HC; Yeh SD; Chen WH; Chiang PH
Kaohsiung J Med Sci; 2012 Aug; 28(8):429-34. PubMed ID: 22892164
[TBL] [Abstract][Full Text] [Related]
20. Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia.
Rosen R; Seftel A; Roehrborn CG
Int J Impot Res; 2007; 19(5):480-5. PubMed ID: 17717526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
